BehaVR and Sumitomo Dainippon Pharma Co, Ltd partner to Advance Virtual Reality for Social Anxiety Disorder

other articles posted on

BehaVR has launched a new partnership aimed at leveraging virtual reality experiences to address critical unmet needs in social anxiety disorder (SAD)

“BehaVR’s technology platform expands on VR’s capability, using real-time biometrics and machine learning to personalize the experience. We believe this offers new possibilities in addressing SAD, and we are excited to explore these possibilities and ultimately bring to market a product that has the potential to change the lives of millions.” – Dr. Peter Buecker

Read Business Wire Read News Medical Life Sciences Read Health Tech Pulse Read IVRHA Read Worcester Business Journal Read Auganix Read Aithority

Releated Posts

View All

Contact our team today to get a customized plan for your organization

Get Started